ASH 2024 | Dr. Bing Han: Advances in Aplastic Anemia and PNH Treatment – Highlights from EBMT-SAAWP Studies

ASH 2024 | Dr. Bing Han: Advances in Aplastic Anemia and PNH Treatment – Highlights from EBMT-SAAWP Studies

From December 7 to 10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, USA. Experts and scholars from around the globe gathered to discuss and exchange insights on the latest research in hematology. During the conference, Dr. Bing Han from Peking Union Medical College provided an on-site review of two significant studies from the Severe Aplastic Anemia Working Party (EBMT-SAAWP) of the European Society for Blood and Marrow Transplantation. Professor Han also shared in-depth analyses of key research topics presented at the meeting. These highlights are summarized below for our readers.
Annual Review | Dr. Jun Guo: Advances in Systemic Therapy for Melanoma in 2024

Annual Review | Dr. Jun Guo: Advances in Systemic Therapy for Melanoma in 2024

Malignant melanocytes can appear in various tissues throughout the body, most commonly in the skin and mucous membranes, and are highly aggressive. With continuous advancements in targeted therapy, immunotherapy, and biological therapy, even advanced melanoma can, in many cases, be managed as a chronic disease. Looking back at 2024, what were the key research developments and treatment strategies in systemic therapy for melanoma? Oncology Frontier invited Dr. Jun Guo, Vice President of the Chinese Society of Clinical Oncology (CSCO) and professor at Peking University Cancer Hospital, to provide an expert review and summary. From Professor Guo’s annual analysis, it is evident that numerous novel treatment strategies have already begun or are poised to impact clinical practice, including some pioneering approaches originating from China.
ASCO GI 2025 | Dr. Rongbo Lin: SYLT-026 Study Marks a Breakthrough in Immunotherapy for MSS-Type Colorectal Cancer

ASCO GI 2025 | Dr. Rongbo Lin: SYLT-026 Study Marks a Breakthrough in Immunotherapy for MSS-Type Colorectal Cancer

Microsatellite stable (MSS) and mismatch repair-proficient (pMMR) metastatic colorectal cancer (mCRC) has shown minimal response to immune checkpoint inhibitors as monotherapy, making combination immunotherapy a key strategy to address this clinical challenge. At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025), a multicenter phase II study led by Dr. Rongbo Lin from Fujian Cancer Hospital was selected for the poster abstract session (Abstract #198). This study evaluates the preliminary efficacy and safety of FOLFOXIRI combined with bevacizumab and cadonilimab in pMMR/MSS mCRC patients.  During the conference, a reporter from Oncology Frontier conducted an in-depth interview with Dr. Rongbo Lin to discuss the study findings.
ASCO GI 2025 | Dr. Lin Shen & Dr. Zhi Peng: PD-L1/TGF-βRII Bispecific Antibody SHR-1701 Improves Efficacy and Protects Bone Marrow in First-Line Treatment of G/GEJA

ASCO GI 2025 | Dr. Lin Shen & Dr. Zhi Peng: PD-L1/TGF-βRII Bispecific Antibody SHR-1701 Improves Efficacy and Protects Bone Marrow in First-Line Treatment of G/GEJA

From January 23 to 25, 2025, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) was held in San Francisco, showcasing significant advancements in gastrointestinal cancer treatment. The Peking University Cancer Hospital presented a series of cutting-edge findings, contributing to global progress in digestive tract oncology. On the first day of the conference, Dr. Zhi Peng from Peking University Cancer Hospital delivered an oral presentation on the latest findings from a Phase III clinical study evaluating the domestically developed PD-L1/TGF-βRII bispecific fusion protein SHR-1701 in first-line treatment for HER2-negative gastric and gastroesophageal junction adenocarcinoma (G/GEJA). Building upon the efficacy improvements previously reported at the European Society for Medical Oncology (ESMO) Congress, the latest data presented at ASCO GI suggests that SHR-1701 combined with chemotherapy may mitigate chemotherapy-induced bone marrow suppression, offering a more effective and safer treatment option for G/GEJA.
Annual Review | Dr. Wenbin Qian：Advancements in CAR-T Cell Therapy for B-Cell Lymphoma

Annual Review | Dr. Wenbin Qian：Advancements in CAR-T Cell Therapy for B-Cell Lymphoma

In recent years, the field of hematologic malignancies has witnessed numerous groundbreaking advancements, with Chinese researchers making increasingly significant contributions, particularly in the area of cellular therapy. Their work has greatly accelerated both academic development and clinical practice in this domain. As we step into the new year, Hematology Frontier has invited Dr. Wenbin Qian from The Second Affiliated Hospital of Zhejiang University School of Medicine to provide an in-depth review of CAR-T cell therapy for B-cell lymphoma, summarizing approved CAR-T products, clinical trial data, real-world outcomes, and ongoing challenges. Additionally, this discussion explores strategies for enhancing CAR-T therapy, including novel targets, dual-target CAR-T designs, and gene-editing improvements, aiming to offer valuable insights for clinical practice and future research directions.
Moving Forward with Determination, Embracing a Promising Future! Dr. Xinan Sheng on Key Advances in the Treatment of Advanced Renal Cancer in 2024

Moving Forward with Determination, Embracing a Promising Future! Dr. Xinan Sheng on Key Advances in the Treatment of Advanced Renal Cancer in 2024

In recent years, some immunotherapy approaches for renal cancer have faced setbacks, failing to meet primary endpoints. However, with ongoing advancements in targeted therapy, immunotherapy, and other treatment modalities, significant progress has been made in managing advanced renal cancer. Notably, the success of multiple large-scale Phase III trials on targeted and immunotherapy combinations has marked the beginning of a new era in first-line treatment for advanced renal cancer. In 2024, several major breakthroughs were achieved. To provide deeper insights, Oncology Frontier invited Xinan Sheng, professor at Peking University Cancer Hospital, to summarize the key research developments that may serve as valuable references for future renal cancer treatment and research.